**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6237**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (14): Pancreatic cancer

Anaesthetic perioperative management of patients with pancreatic cancer

De Pietri L *et al*. Anaesthetic management in pancreatic cancer surgery

Lesley De Pietri, Roberto Montalti, Bruno Begliomini

**Lesley De Pietri, Bruno Begliomini,** Division of Anaesthesiology and Intensive Care Unit, Azienda Ospedaliero-Universitaria di Modena-Policlinico, 41100 Modena, Italy

**Roberto Montalti**,Transplantation Surgery, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 41100 Modena, Italy

**Author contributions:** De Pietri L conceived and designed the review; Montalti R drafted the article; Begliomini B revised the manuscript.

**Correspondence to: Dr. Lesley De Pietri,** Division of Anaesthesiology and Intensive Care Unit, Azienda Ospedaliero-Universitaria di Modena-Policlinico, # 71 via del Pozzo, 41100 Modena, Italy. lesley.depietri@yahoo.it

**Telephone:** +39-59-4225864 **Fax:** +39-59-4223765

**Received:** October 10, 2013  **Revised:** January 6, 2014

**Accepted: January 20, 2014**

**Published online:**

**Abstract**

Pancreatic cancer (PC) remains a significant and unresolved therapeutic challenge. Currently, the only curative treatment for pancreatic cancer is surgical resection. Pancreatic surgery represents a technically demanding major abdominal procedure that can occasionally lead to a number of pathophysiological alterations resulting in increased morbidity and mortality. Systemic, rather than surgical complications, cause the majority of deaths. Because patients are increasingly referred to surgery with at advanced ages and because pancreatic surgery is extremely complex, anaesthesiologists and surgeons play a crucial role in preoperative evaluations and diagnoses for surgical intervention. The anaesthetist plays a key role in perioperative management and can significantly influence patient outcome. To optimise overall care, patients should be appropriately referred to tertiary centres, where multidisciplinary teams (surgical, medical, radiation oncologists, gastroenterologists, interventional radiologists and anaesthetists) work together and where close cooperation between surgeons and anaesthesiologists promotes the safe performance of major gastrointestinal surgeries with acceptable morbidity and mortality rates. In this review, we sought to provide simple daily recommendations to the clinicians who manage pancreatic surgery patients to make their work easier and suggest a joint approach between surgeons and anaesthesiologists in daily decision making.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Pancreatic cancer; Pancreatic surgery; Perioperative anaesthesia management

**Core tip:** Currently, the only curative treatment for pancreatic cancer is surgical resection. However, this type of surgery is still burdened by considerable morbidity due to its complexity and to the type of referred patients (elderly and with many co-morbidities). We believe that anaesthetic management with proper surgical approaches can play a key role in the outcome of the patient. Simple perioperative precautions in anaesthetic management (patient risk assessment, fluids management, prevention of surgical site infection, thromboprophylaxis, intraoperative ventilation, and intensive postoperative management) can help to ensure that these surgical operations are performed with reasonable assurance.

De Pietri L, Montalti R, Begliomini B. Anaesthetic perioperative management of patients with pancreatic cancer.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the United States and the sixth in Europe, with the lowest survival rate for any solid cancer worldwide[[1](#_ENREF_1)]. It is the most lethal type of digestive cancer and exhibits a five year survival rate of 5% with a range that is correlated with staging and location. The main reason for this extremely poor prognosis is that less than 15% of patients are diagnosed with resectable tumours[[2](#_ENREF_2)]. Currently, the only curative treatment for PC is surgical resection, although even for resectable tumours, cure is still rare (5-year survival rate of approximately 15%-20%)[[3](#_ENREF_3)].

Pancreatic surgery represents a challenging and technically demanding major abdominal procedure that occasionally results in a number of pathophysiological alterations during the early postoperative period that account for increased rates of morbidity and mortality.

Systemic, rather than surgical complications, cause the majority of PC-related deaths[[4](#_ENREF_4)]. More than 80% of PCs are diagnosed in patients older than 65 years. Many PC patients are or have been heavy smokers[[5](#_ENREF_5), [6](#_ENREF_6)], and nearly 80% of PC patients have either frank diabetes or impaired glucose tolerance[[7](#_ENREF_7)]; venous thromboembolism remains a major complication of PC[[8](#_ENREF_8)]. For these reasons, PC patients who undergo a major abdominal surgery are at increased anaesthesiological risk. In the light of these issues, it is important to refer these patients to centres with a high volume of operations where a multidisciplinary approach is applied to improve the overall outcome. Moreover, careful patient selection is fundamental.

In this setting, the anaesthesiologist plays a crucial role during preoperative evaluation, which together with a proper surgical approach and a concerted effort with medical physicians, radiation oncologists, gastroenterologists and interventional radiologists is crucial for a favourable perioperative outcome[9]. Patient outcome can be significantly influenced by anaesthesiological management (Table 1), starting with patient stratification and selection, continuing throughout the surgical operation and finishing with postoperative care (Intensive Care Unit, recommendations for the ward)[10].

**PREoperative management**

***Informed patient consent***

Despite recent developments in operative technique and postoperative care, pancreatic surgery remains associated with high morbidity and mortality. Postoperative complications such as primarily pancreatic fistula, haemorrhage, abscess, and delayed gastric emptying still occur at a frequency of 30% to 60%, resulting in a mortality rate of 1% to 5%[11]. For this reason and due to the lethality of the pancreatic cancer despite surgical treatment, the patient should be informed about the therapeutic procedure and any potential complications or disabilities to facilitate a conscious involvement in the decision-making process.

In the case of patients of advanced age who require pancreatic surgery, formal mental status testing can help determine whether a patient can be considered capable of making this type of decision.

Dementia is an extreme predictor of poor outcome, exhibiting surgical mortality rates that are increased by 52%[12]. The decision to classify an elderly patient eligible for surgery cannot exclude preoperative mental status.

***Preoperative risk assessment***

A complete history, physical, laboratory examinations, and an assessment of the surgical risks should be included in the preoperative evaluation of an elective surgery.

Currently, the definition of preoperative risk remains vague and difficult to standardise, as it is influenced by many variables attributed to patient- and surgery-specific variability[13]. Recently, a variety of scoring systems has been developed, and the Physiologic and Operative Severity Score for the Enumeration of Mortality and morbidity (POSSUM) model by Copeland *et al*[14] was recognised as the most effective for general surgery[15]. This model, which uses scores relating to 12 physiological and 6 operative variables, was developed to postoperatively predict 30-d mortality and morbidity. The application of the predictive POSSUM and P-POSSUM (Portsmouth modification of POSSUM)[16] models to cases of pancreatic surgery has generated conflicting results. The implementation of this scoring system in the routine practice has proven to be difficult, and a recent review by Wang *et al*[17] has found POSSUM to overpredict postoperative mortality. Despite these limitations, there is still a role for POSSUM as a useful tool in pancreatic surgery. Individual POSSUM scores should not preclude pancreatic resection in clinical practice but might help surgeons modify expectations of postoperative outcomes[18].

Due to the limitations of the POSSUM model, more trials are needed to adequately evaluate this scoring system in predicting postoperative mortality for pancreatic surgery.

***Evaluation and optimisation of preoperative physical conditions and medications***

A growing number of old patients benefits from a surgical procedure[19]. Age is an independent risk factor of postoperative mortality and postoperative complications and can cause a gradual progressive loss in the biological reserves for maintaining physiological homeostasis under stress. In addition, an increasing number of patients present with one or more age-related chronic conditions, which further decrease their ability to respond to stress. Cardiac and pulmonary diseases are the most frequently observed co-morbidities that anaesthetists and surgeons must manage during this complex surgery.

A complete history of prior medical and surgical conditions and a full medication list are particularly important[20, 21].

**Cardiovascular risk evaluation:** Cardiovascular complications are among the most common and significant postoperative problems in elderly patients. A practical guideline for perioperative cardiovascular evaluation for non-cardiac surgery has been proposed by the American College of Cardiology and American Heart Association Task Force[22]. Patients should be assessed using an approach that considers clinical predictors, the risk of the proposed operation, and the functional capacity.

Ageing is accompanied by increased vascular and ventricular stiffness, diastolic dysfunction and an increased risk of heart failure[23]. Diastolic dysfunction even with a normal or supranormal ejection fraction might elicit a significant effect on the perioperative outcome and management of elderly patients[12]. Diastolic dysfunction might significantly affect perioperative haemodynamics, response to fluid shifts, anaesthetic drugs and other perioperative medications.

Patients with cardiovascular diseases are sensitive to haemodynamic instability and often require increased filling pressures to generate an adequate cardiac output. The anaesthetist must carefully manage fluids during the operation to avoid overload or rapid volume administration. Moreover, the anaesthetist must maintain a normal haemoglobin value (Nair *et al*[24]] demonstrated that anaemia was strongly associated with diastolic dysfunction in patients with coronary artery disease) and, if possible, must choose volatile anaesthetics that appear to improve diastolic parameters (in contrast to propofol, which elicits the opposite effect) as measured by echocardiography[25]. Thoracic epidural analgesia should be strongly suggested, not only for pain management and for decreasing respiratory complications but also because its use appears to improve cardiac function by improving the diastolic characteristics of the left ventricle[26, 27].

**Prophylactic perioperative β-blockade:** In general, cardiovascular medication should not be discontinued prior to surgery. In the perioperative setting, β-blockers are not contraindicated in patients with diastolic heart failure and should be continued in patients with systolic heart failure. However, caution is warranted with the acute administration of β-blockers in situations of decompensating systolic heart failure. Nonetheless, given the risk of acute withdrawal, β-blockade in patients with coronary artery diseases or coronary artery disease risk factors should not be discontinued preoperatively. Rather, perioperatively increasing the dosage of the patient’s β-blockade regimen would most likely be beneficial[28-30].

If a patient who is scheduled for elective pancreatic surgery requires a new prescription, it should be started at least 1 month prior to the procedure to allow for dose adjustment[31, 32].

**Pulmonary risk evaluation:** Pulmonary complications such as pneumonia, failure to wean, and postextubation respiratory failure represent the second most frequent types of postoperative complication following wound infection, with an estimated incidence rate ranging from 2.0% to 5.6% following surgery[33, 34]. Pulmonary disease increases the risk of postoperative complications, accounting for 40% of postoperative complications and 20% of deaths[35]. Age-related changes, such as increased closing volumes and decreased expiratory flow rates can predispose older patients to pulmonary complications.

Some postoperative pulmonary complication (PPC) predictors after pancreatic surgery are summarised in Table 2 (modified from Canet J *et al*[36]).

Identifying the patients who are at high risk for PPCs, can help the anaesthetist to design individually tailored management approaches[37-39]. Pharmacologic measures for managing these complications are either unavailable or limited, and as a result, treatments must be based on physical therapy and respiratory support ventilation.

Finally, the ability to predict PPCs would enable clinicians to give patients more precise risk assessments, thereby facilitating their decision making.

***Nutritional status and mechanical bowel preparation***

The prevalence of malnutrition is high in patients who are submitted for surgery and ranges from 35% to almost 60%[40]. Malnutrition has been consistently associated with impaired immunity[41] and can lead to increased complications, such as pressure ulcers, delayed wound healing, increased risk of infections, impaired muscular and respiratory functions[42], as well as increased mortality and poor clinical outcomes.

Nutritional status should be determined because nutritional deficiencies are common in patients who have undergone pancreatic resection for malignant tumours. Because malnutrition is potentially reversible with appropriate nutritional support, the early identification of high-risk patients is crucial, and preoperative malnutrition screening is required to identify and to treat the malnutrition[43]. Recently, the routine screening of patients to identify risk of malnutrition has been recommended by many national, international, and specialist organisations[44, 45]. The malnutrition universal screening tool (MUST) for adults was recently validated by several studies, which have demonstrated that as a screening procedure, MUST is rapid and easy to use[46, 47].

The MUST appears to be a valid and easy screening tool for pancreatic surgery[20], which can identify patients at high risk for major complications and death. Furthermore, the MUST can prompt the implementation of effective nutritional interventions to reduce poor outcomes and thereby optimise the use of postoperative critical care beds and hospital resources.

As soon as malnutrition is recognised, preoperative nutritional supplements should be provided when possible. This supplementation can include high-energy foods, vitamins, enteral feedings, or, if necessary, total parenteral nutrition.

***Mechanical bowel preparation***

“Enhanced recovery” or “fast-track” (FT) programmes, which were first developed by Kehlet *et al*[48], are structured interdisciplinary strategies that have been introduced to optimise peri-operative care and to accelerate post-operative recovery[49]. A major intervention principle of this approach is the avoidance of preoperative mechanical bowel preparation (MBP), which has been employed as a preventative measure in gastrointestinal surgery for more than a century as an essential factor for avoiding infectious complications and anastomotic dehiscence. FT programmes, which exclude MBP, have been proposed more often in other surgical fields (elective colorectal, gastro-oesophageal and aortic surgery) and rarely have been applied to liver and pancreatic surgery[50]. The application of MBP in this type of surgery has been evaluated by limited studies (a retrospective case-control study by the Jefferson University[51] and a review by Salvia *et al*[52]), which have shown that it did not improve perioperative outcomes. At our institution, MBP has been excluded from clinical practice in pancreatic surgery. A recent review examined and compared the application of FT protocols with standard care in elective liver and pancreatic surgeries, showing that FT programmes can enhance post-operative recovery and reduce the length of hospital stays with no increase in adverse events, such as re-admissions, morbidity or mortality[53, 54]. The avoidance of MBP, together with other measures including the application of epidural analgesia, the prevention of intra-operative hypothermia, fluid restriction, post-operative nutritional care and early mobilisation, collectively represent essential elements of a FT programme that is warranted for complex surgical operations such as pancreatic resection[55, 56]. In our experience FT programmes for hepatopancreatic resections appear to be safe and associated with a reduction in the length of hospital stays.

***Risk stratification, rationale for thromboprophylaxis, and recommendations***

In patients undergoing general and abdominal-pelvic surgery, the risk of venous thromboembolism (VTE) varies depending on both patient- and procedure-specific factors[57]. Pancreatic cancer is among the most common malignancies associated with thrombosis, as it occurs in 50% of total patients[58]. Prophylaxis against postoperative venous thromboembolism should be tailored to the patient's level of risk. A model (the Caprini score) that can potentially be used for such purposes estimates VTE risk by adding points for various VTE risk factors[59].

Pharmacological prophylaxis reduces the risk of pulmonary embolism by 75% in general surgical patients and by 57% in medical patients[60]. The use of low-molecular-weight heparins (LMWHs) to prevent thrombotic events in these patients is a common and well-documented practice.

Current recommendations strongly advise effective and preventive strategies for all hospitalised patients who are defined as moderate to high risk for VTE and are awaiting pancreatic surgery.

Low molecular weight heparins (LMWHs) appear to be effective and are potentially associated with a lower risk of bleeding when the first dose is administered 12 h preoperatively[57, 61]. We recommend the administration of LMWH from the day prior to surgery to all patients scheduled for pancreatic cancer surgery.

In the case of patients who are receiving anticoagulants or antiplatelet therapy and require an elective surgery or procedure, the actual guidelines addressing their management are underlined in Table 3 and are modified from Douketis *et al*[62].

**Intraoperative management**

***Combined general and epidural anaesthesia***

The use of thoracic epidurals is widespread for intraoperative and postoperative analgesia. Thoracic epidural anaesthesia (TEA) reduces sympathetic activity, thereby influencing the perioperative function of vital organ systems. Thoracic epidural anaesthesia has been used widely to provide excellent pain relief, to attenuate the catabolic response to abdominal surgery, to lower the incidence of pulmonary morbidity, to decrease the cardiac metabolic demand, to reduce the risk of thromboembolic complications, to promote the recovery of intestinal function and to minimise motor blockade[63, 64]. Moreover, epidural anaesthesia and mild hypercapnia have been shown to increase subcutaneous tissue oxygenation[65].

The combination of general anaesthesia and thoracic epidural anaesthesia has become the technique of choice at many institutions for major abdominal surgery[66, 67].

Recent studies have suggested that for some types of cancer, TEA might also reduce the rate of recurrence after surgical resection. The possibility of reducing tumour recurrence makes the combination of general anaesthesia and TEA even more appealing, despite the existence of certain contraindications[68, 69].

TEA represents a powerful tool that is available to anaesthesiologists for perioperative intervention in pancreatic surgery. At our University Medical Centre, we strongly address its use in the context of multimodal intervention.

***Prevention of surgical site infection***

Surgical site infections continue to represent a substantial source of morbidity and mortality in the surgical patient population. They are the second most common cause of nosocomial infection after urinary tract infections and account for approximately 17% of all hospital-acquired infections[70].

Increasing evidence indicates that anaesthesiologists play a prominent role in the prevention of surgical site infections. Anaesthesiologists are involved in the administration of antibiotics, in the use of supplemental oxygen, in the maintenance of normothermia and normoglycaemia, in the perioperative fluid management and in the administration of blood transfusions[71, 72]. Therefore, decreasing surgical site infections depends on the optimisation of some perioperative conditions, which are generally controlled by anaesthesiologists.

***Antimicrobial prophylaxis***

The anaesthesiologist can play a simple but effective role in the prevention of surgical site infections by ensuring the administration of appropriate antimicrobial prophylaxis [73, 74].

Current recommendations state that the infusion of the first dose of drug should begin within 30-60 min of incision. This period can be lengthened to 120 min for drugs such as vancomycin, where high infusion rates have been associated with complications[75]. The drugs used should be defined in advance for each intervention, including alternatives in the event that the patient presents with any contraindication for the frontline antibiotics. The determination of the ideal preoperative antibiotic therapy for a patient who is awaiting pancreatic surgery requires efforts by a multidisciplinary team (anaesthesiologist, surgeon and microbiologist). A proper and effective antimicrobial prophylaxis should be based upon the application of a standard protocol and quality management[76].

Concerning the duration and dosage of prophylaxis, the guidelines generally recommended a single standard intravenous therapeutic dose of antibiotic in the majority of procedures. Repeated doses have only been indicated in special circumstances such as prolonged surgery with a duration longer than the half-life of the antibiotic used or cases of major blood loss. This recommendation is based on published evidence, which suggested that the administration of short-duration prophylaxis is equally effective as longer-duration prophylaxis in the prevention of surgical site infections[77, 78]. It is advisable to administer at least two antibiotic doses during pancreatic surgery.

***Avoid hypothermia***

Mild perioperative hypothermia (core body temperature 34°C-36°C) is commonly observed in surgical patients. The complications of mild perioperative hypothermia have been studied extensively and include increased duration of hospitalisation, increased intraoperative blood loss and transfusion requirements, increased adverse cardiac events, and an increase in patient thermal discomfort in the recovery room[79, 80]. The effects of mild hypothermia on surgical site infections have also been studied. The major relation between hypothermia and increased surgical site infections is thought to be a decrease in subcutaneous tissue perfusion mediated by vasoconstriction[81, 82]. The reduced oxygenation of the wound is responsible for reduced oxidative killing elicited by neutrophils and for the reduced production of superoxide radicals for any given oxygen tension[80].

Intraoperative core temperature monitoring (oesophageal temperature probe) and adequate control of body temperature are essential during pancreatic cancer surgery[83]. Heat loss during the first hour of anaesthesia is generally a result of the redistribution of core-to-peripheral temperature gradients caused by an anaesthetic-induced decrease in vasoconstriction. The exposure of the large bowel, significant amounts of fluids administered, and long surgical procedures represent other causes of intraoperative hypothermia. Actively pre-warming patients for 2 h prior to the induction of either general or regional anaesthesia[80] using forced-air warming blankets together with fluid-warming systems represents an important way to keep patients normothermic[84].

***Glucose control***

Hyperglycaemia is associated with an increased risk of morbidity and mortality[85]. Several studies have shown the negative effects of hyperglycaemic phases during hospitalisation on the rate of nosocomial infections, length of hospital stay and mortality[71, 86]. In a recent trial, the use of insulin infusions to maintain serum glucose at less than 110 mg/dL in critically ill patients decreased the mortality rate from 8.0% to 4.6%, regardless of diabetic status[87]. In subsequent studies, the concept of intensive glucose control was modified towards less-extreme blood glucose levels because of dangerous hypoglycaemic episodes that were attributable for worse patients outcomes than that originally reported[88, 89]. Intraoperative glucose control should be a standard practice during long and complex surgical procedures to reduce perioperative complications.

The optimal glucose level during the perioperative period has not been prospectively investigated, and the available data from recent reports do not indicate a specific threshold for the treatment of hyperglycaemia. There is some evidence that keeping glucose levels within a range of 110-180 mg/dL and not limiting the treatment to values higher than 200 mg/dL is safe and appropriate.

It is important not only to limit glucose control during the intraoperative period but also to continue insulin infusion during the postoperative period. The frequent and precise measurement of glycaemia must become a standard of pancreatic cancer patient management both during surgical procedures as well as during the postoperative period[90].

***Blood transfusion management***

Several published studies have demonstrated how blood product transfusions increase the postoperative risk of infection[91, 92].

Published guidelines generally concur that although transfusions are not beneficial when the haemoglobin concentrations are greater than 100 g/L, they confer benefit when the haemoglobin concentrations are less than 60-70 g/L. Studies that have described transfusion management in Jehovah’s witnesses have shown that morbidity and mortality only increase postoperatively for each gram of decrement when the haemoglobin concentration is less than 70 g/L[93]. Patients with cardiovascular diseases exhibit a significantly increased rate of postoperative mortality, and for this reason, the transfusion trigger should be different for patients with or without cardiovascular disease[94, 95]. Although multiple trials have assessed the effects of transfusion thresholds on patient outcome, the literature is insufficient for defining a transfusion trigger in surgical patients with substantial blood loss. In the light of recent findings, the transfusion management of surgical patients should be patient specific and should not be based on arbitrary laboratory values but guided by patient covariables[96-99]. As underlined by the recent guidelines on perioperative bleeding management of the European Society of Anaesthesiology (ESA), we suggest a target haemoglobin concentration of 7-9 g/dL and the guidance of transfusions based on levels of serum lactate, base deficit, and central venous oxygen saturation[100].

***Intraoperative fluid management***

Optimal perioperative fluid management remains highly challenging, particularly in patients undergoing major abdominal surgery[101-103]. Perioperative physicians generally administer intravenous fluids to replace fasting deficits, third space losses, and blood loss to maintain adequate cardiac output, blood pressure, and urine output.

Fluid excess can have a negative impact on cardiac, pulmonary, bowel function and wound healing, predisposing the patient to tissue oedema and anastomotic breakdown[104, 105]. In contrast, excessive fluid restriction can expose the patient to hypovolaemia and hypoperfusion[106]. Surgery causes inflammation and a corresponding release of mediators that can induce local tissue oedema[107]. Anaesthetists generally manage perioperative fluid administration by using unmonitored fixed fluid regimens and estimating fluid loss.

In recent years, restrictive fluid management has replaced this approach, and the concept of fast-track surgery has challenged the traditional administration of large amounts of fluids during surgery[108, 109].

These findings have prompted fervent discussion on how liberal or restrictive perioperative fluid management should be applied, and several randomised controlled trial have attempted to settle this issue[104, 108, 110, 111].

Due to the lack of consensus on the optimal implementation of fluid management, a new and more precise approach based on goal-directed fluid therapy and individualised fluid administration has been developed[103]. Goal-directed fluid optimisation has markedly increased tissue oxygen tension and microcirculatory perfusion in both healthy and perianastomotic tissues compared to the restricted fluid strategy[106, 112, 113].

Central venous pressure (CVP) remains the most widely used clinical marker of volume status, despite numerous studies indicating no association between CVP and circulating blood volume[114]. Because of this limitation, central venous and pulmonary artery occlusion pressures, which are the only variables for guided fluid therapy and optimised preload, are not recommended. Dynamic parameters such as stroke volume variation or pulse pressure variation provide a more favourable prediction of fluid responsiveness. Individualised goal-directed fluid therapy, particularly oesophageal Doppler-guided fluid optimisation, has been shown to improve patient outcomes and to reduce the length of hospital stays compared with conventional fluid replacement[115]. Doppler-guided fluid boluses appear to improve clinical outcomes, particularly in elderly and frail patients[116, 117]. This method, however, cannot be universally performed for practical and financial reasons[118].

Using a “goal-directed” approach, it is generally possible to replace lost plasma, whereas the extracellular compartment cannot currently be monitored. Therefore, losses from the latter should be replaced based on the protocol suggested by Chappel *et al*[101], which involves the substitution of insensible perspiration with 1 mL/kg per hour during abdominal surgeryand does not include the possibility of primary fluid consumption by the third space, the existence of which is denied[119].

The optimal solution for volume replacement and optimisation remains an ongoing issue of heated debate. The goal of perioperative fluid management is to maintain fluid balance and to minimise the possible risks by choosing the right fluid at the right time.

Colloids are criticised because of their ability to diffuse into the interstitium, making further extravasation more likely[120], because of the cumulative and persistent effects related to their infusion[121] and, finally, because of safety concerns. Recent studies of the potential increase in the risk of bleeding and acute kidney injury following the application of various colloids have shown that the use of hydroxyethyl starch appears to be associated with an increased need for dialysis[122] and might even increase mortality in patients with sepsis[123].

Current evidence suggests that beyond fluid composition, the timing and volume of the administered fluid represent two additional factors that are likely to influence perioperative patient outcome. For patients with mild-to-moderate volume deficits, crystalloids are still the first choice. In the case of severe volume depletion, we recommend starting fluid resuscitation with a colloid to rapidly reverse volume deficits and ensure oxygenation and then to switch to crystalloids once the patient approaches euvolaemia.

Goal-directed fluid management enables appropriate use of fluids, vasopressors, and inotropes, and results in improved outcomes. The vasodilatatory effect of anaesthetic cannot be ignored and must be expected to terminate at the end of surgery. Treating vasodilatation with crystalloids or colloids can be a mistake in all euvolaemic patient, whereas vasopressor infusion during surgical operation can help in avoiding excessive fluid overload[124, 125].

***Optimisation of intraoperative ventilation***

Postoperative pulmonary complications following major upper abdominal surgery increase morbidity, mortality, the length of hospital stay and costs[33]. Reduced lung inflation represents one of the basic mechanisms of postoperative pulmonary complications. The adjustment of the body positioning from upright to supine itself can reduce the resting lung volume by approximately 0.8-1.0l[126]. The additive effect of supine positioning, general anaesthesia, and abdominal incisions significantly reduces functional residual capacity and increases airway resistance. In addition, during the induction of anaesthesia, most of the general anaesthetics further reduce functional residual capacity. The combination of these effects predisposes patients to atelectasis with the risks of hypoxemia and infection. Additionally, postoperative pain and the use of analgesics can contribute to a reduced tidal volume and impaired clearing of secretions, depending on adequate coughing and deep breathing[126, 127].

Mechanical ventilation is mandatory in patients undergoing general anaesthesia. High tidal volumes can overdistend non-injured lungs, particularly in non-dependent lung tissues. The non-aerated atelectatic lung regions are prone to repeated collapse and re-expansion of the alveoli, causing shear stress and diffuse mechanical damage of the alveoli. During surgical procedures, both phenomena can induce stress in non-injured lung tissues, triggering local inflammation[128, 129]. Retrospective and prospective studies have shown the potential beneficial effects of reduced tidal volumes in patients who are on short-term mechanical ventilation following surgery[130]. Protective mechanical ventilation using reduced tidal volumes can accordingly reduce ventilator-associated lung injury. The application of positive end expiratory pressure (PEEP) can prevent alveolar collapse and atelectasis formation, and recruitment manoeuvres can support the beneficial effects of PEEP during short-term ventilation[131]. Effective anaesthesiological management during pancreatic surgery should involve the application of a protective ventilation strategy (lower tidal volumes < 8 mL/kg, PEEP = 6-12 mmHg and recruitment manoeuvres) to improve respiratory function during the postoperative period following abdominal surgery and to reduce the clinical signs of pulmonary infection during the postoperative period[132].

***Intraoperative thromboprophylaxis***

The use of low-molecular-weight heparins (LMWHs) to prevent thrombotic events in these patients represents a common and well-documented practice. Effective pharmacological thromboprophylaxis includes the administration of low molecular weight heparin (LMWH) from the day prior to the surgery. In addition to this useful approach mechanical prophylaxis including graduated compression stockings and intermittent pneumatic compression is highly recommended during the surgical operation and during the postoperative period until the risk of bleeding has diminished and the application of new pharmacological prophylaxis might be initiated[57, 60].

 Thromboelastography can play a potential role, despite its limitations, as a valuable tool for the evaluation of the entire perioperative coagulation process and hypercoagulability changes, as well as for increasing patient safety through more effective management of antithrombotic therapy[133, 134].

**Postoperative management**

Over the past 20 years, surgery and anaesthesia for patients undergoing abdominal surgery have undergone immense development. A novel concept of perioperative patient care following surgical abdominal procedures has emerged. Fast track programmes, a new concept of enhanced recovery after surgery and the implementation of multimodal rehabilitation, have heavily influenced this modern change, optimising perioperative care, accelerating recovery and reducing hospital stays and costs. The objective of this integrated approach between surgeon, anaesthetist, nurses and physiotherapist is to reduce the impact of surgery on patient homeostasis. The main pillars of this new management are those shared by fast track surgery and can be summarised as follows: (1) Reduction of surgical invasiveness (early removal of drains, nasogastric tube, small incisions, pharmacological stimulation of the gut); (2)Pain relief/non-opioid oral analgesia; (3)Early oral nutrition/goal-directed fluid therapy; (4)Intensive postoperative ambulation and prevention of venous thromboembolism; and (5)Intensive respiratory rehabilitation.

All of these basic points, combined with the prevention of intraoperative hypothermia, neural blockades[135], maintenance of euglycaemia, and the development of goal-directed fluid therapy contribute to the reduction of surgical stress.

A systematic review of the literature regarding peri-operative care in pancreatic cancer surgery has revealed a limited number of studies providing low levels of evidence[50, 54, 136]. Despite their potential weaknesses, the studies detailed above have demonstrated that implementation of fast-track peri-operative care pathways is feasible in pancreatic surgery and can be associated with reduced length of stay, reduced relevant hospital costs and no increase in morbidity, 30-day mortality or re-admission rates.

***Early nasogastric tube, catheter and drain removal***

**Nasogastric tube:** Nasogastric tubes have been routinely used following abdominal surgery until normal bowel function is restored, following the notion that gastric decompression resulting from decreased air and fluid accumulation can prevent abdominal distension, nausea and vomiting. Many studies have subsequently questioned this practice, advising against its routine use. In fact, prophylactic nasogastric tube aspiration is associated with pulmonary complications[137] and significant patient discomfort. A recent study on the implementation of fast-track recovery pathways in pancreatic surgery[138] has underlined the advantages of the early removal of nasogastric tubes and early oral feeding in terms of incidence of delayed gastric emptying and earlier bowel activity. Given the risk of pulmonary complications, significant patient discomfort and lack of benefit associated with prophylactic nasogastric tube aspiration, this practice should not be routinely used[139, 140].

Consistent with a recent study, in our daily practice, we remove nasogastric tubes on postoperative day 1 only if the tube drainage amount is less than 300 mL or at the end of surgery in cases of distal pancreatectomy which makes delayed gastric emptying less frequent[52].

**Abdominal drains:** The presence of an abdominal drain represents a significant impediment to achieving early and appropriate levels of mobilisation. Several randomised trials have not found any benefit of prophylactic drains after surgical operations, such as cholecystectomy[141], colorectal surgery[142] or hepatectomy[143]. Rather, these prospective randomised studies found that routine drainage resulted in an increased frequency of complications and no difference in outcome.

Because pancreatic surgery is associated with high rates of morbidity, the purpose of prophylactic drainage is to prevent fluid collection and to aid in the early detection of anastomotic leak and associated haemorrhage. Following pancreatectomy, the use of a prophylactic drain is supported by the belief that the early detection of pancreatic fistulae through the measurement of amylase in the draining fluid will allow for the efficient management and the avoidance of major complications[144]. Despite reports of randomised, control trials and cohort studies that do not support the use of drains, most surgeons routinely place prophylactic intraperitoneal drains at the time of pancreatic resections[145, 146]. Evidence-based practice guidelines for drain management during pancreatectomy remain to be established despite the remarkable number of studies that are available to help guide practice.

At our University Hospital, abandoning drainage during pancreatic surgery is believed to be unsafe, and according to Kaminsky *et al*[146], it is reasonable to suggest a practice of selective drainage based on the presence of risk factors. The presence of soft pancreas texture, a small pancreatic duct diameter, increased intraoperative blood loss (>200 mL) and prolonged operative time are risk factors that reflect abdominal drains. In the case that patient is doing well and the drain amylase levels are below 5000 U/L, drains (on POD1) can be safely removed on POD 3 in patients with low risk of pancreatic fistulae.

***Early oral nutrition***

The restoration of normal gastrointestinal function to allow adequate food intake and rapid recovery is one of the primary objectives of postoperative care. A meta-analysis of controlled trials of early enteral or oral versus ‘nil by mouth’ feeding after gastrointestinal surgery indicated no clear advantage to continued patient fasting after the elective gastrointestinal resection[147].

Concerning nutrition, studies have clearly found that allowing eating/drinking until late the day prior to surgery and commencement of eating/drinking soon after surgery has many advantages[148, 149]. Through the earlier intake of fluids and solids, the gastrointestinal system is less affected with an earlier initiation of normal intestinal activity.

An interesting review analysing which feeding routine was more favourable following pancreatoduodenectomy revealed no consensus in terms of postoperative nutrition of patients who had undergone pancreatic surgery. Current European guidelines recommend routine enteral feeding after pancreatoduodenectomy, whereas the American guidelines do not. Gerristen *et al*[150] concluded that there is no evidence to support routine enteral or parenteral feeding after pancreatoduodenectomy, whereas the oral diet appears to be the best feeding strategy.

At our University Hospital, it is common to allow the patient to take clear liquids from postoperative day (POD) 1 but not before 6 hours postoperatively and a light diet from POD 2, in the absence of any complications. In patients at risk of postoperative complications such as pancreatic fistulae or abdominal collections, we advocate the use of combined parenteral and enteral nutrition[52].

***Total pancreatectomy and postoperative glycaemic control***

Total pancreatectomy, usually performed for the treatment of multifocal disease or in case of atrophic, soft, friable remnant pancreatic tissue is responsible of endocrine and exocrine insufficiency. In addition to the absence of insulin, the endocrine abnormalities accompanying total pancreatectomy include both glucagon and pancreatic polypeptide deficiencies, which appears to play a key role in the increased hepatic insulin resistance observed in pancreatogenic diabetes[151]. Moreover, following pancreatectomy, insulin receptors are upregulated peripherally, rendering patients uniquely sensitive to hormone replacement[152].

This type of diabetic condition is defined “pancreatogenetic” diabetes and is often considered to be different from type 1 and 2 diabetes. This diabetic state is commonly described as “brittle”, as a result of enhanced peripheral insulin sensitivity, decreased hepatic insulin sensitivity and reduction of glucagon secretion. The resulting labile glycaemic control is characterized by periodic episodes of both hyper and hypoglycaemia. [153, 154].

In recent years, studies have shown that diabetes following total pancreatectomy is not necessarily associated with poor glycaemic control, and the majority of cases exhibit equivalent biochemical controls compared to the normal type 1 diabetic population[155, 156].

Recently, the development of accurate, continuous blood glucose monitoring devices, particularly closed-loop systems, for computer-assisted blood glucose control in the intensive care unit have been reported to assist in obtaining favourable glycaemic control in patients with pancreatogenic diabetes following pancreatic resection[157].

The hyperglycaemia induced by surgical stress cannot be controlled using the conventional sliding scale method [158], whereas the perioperative use of an artificial endocrine pancreas enables strict glycaemic control of euglycaemia without severe hypoglycaemia[159, 160].

Modern pancreatic enzyme formulations have improved exocrine insufficiency, facilitating glycaemic control due to the avoidance of malabsorption[155].

The enhanced patient understanding of the consequences of total pancreatectomy, early education on diabetes (all patients should consult an endocrinologist immediately following their operation), advances in medical therapies, and blood glucose monitoring might all have contributed to enhanced glycaemic control[161].

***Goal-directed fluid therapy***

Early oral nutrition has to be associated to the individualised postoperative fluid therapy that is administered in accordance to the optimisation of stroke volume. Dynamic parameters such as stroke volume or pulse pressure variation can provide a more favourable prediction of fluid responsiveness. Oesophageal Doppler-guided fluid optimisation has been shown to improve patient outcomes, although this method cannot be performed on conscious patients[116, 117]. Fluid challenges and the leg-raising test can represent simple and valid alternatives[118]. Thus, oral nutrition has clearly be associated with a progressive decrease of intravenous fluids.

***Pain relief/non opioid oral analgesia***

One aim of fast track surgery is to obtain favourable pain control, which is intended to enable patient mobilisation, coughing and early nutrition. One of the modern principles for analgesia is the concept of opioid-sparing, which enhances recovery by avoiding the opioid-related side effects. In major abdominal procedures, the administration of continuous thoracic epidural analgesia with local anaesthetics has been demonstrated to be the most efficient technique to obtain optimal analgesia, allowing for early mobilisation, reducing postoperative ileus and pulmonary morbidity[162], and therefore acting as an important component of multimodal recovery strategies[163, 164]. A mid-thoracic epidural activated prior to the initiation of surgery also blocks stress hormone release[165] and attenuates postoperative insulin resistance[166, 167].

Fast-track clinical pathways in the peri-operative care of patients undergoing pancreatic resection provide for a catheter placed in the midthoracic level at T8/9 to achieve both analgesic and sympathetic blocks[168].

Small doses of epidural opioids have been shown to act in synergy with epidural local anaesthetics in providing analgesia, allowing reduced dosages of both agents[169].

For break-through pain, non-steroidal anti-inflammatory drugs and bolus epidural bupivacaine should be administered whilst the epidural is running. Non-steroidal anti-inflammatory drugs should be administered just prior to the removal of the epidural and continued until and/or after discharge.

As the optimal duration of continuous postoperative mid-thoracic epidural analgesia has not been established in well-designed randomised trials, we suggest that two-to-three days might be a sufficient period for pancreatic surgery.

Patient-controlled analgesia using intravenous opioids does not provide the same efficient analgesia and elicits less beneficial physiological effects on surgical stress responses compared to local epidural anaesthetic techniques. However, it is performed whenever contraindications prevent the execution of peridural analgesia.

***Intensive postoperative ambulation and prevention of venous thromboembolism***

Among the standardised clinical pathways, which represent the basis of the fast-track programme, early mobilisation is a cornerstone. It has been shown to play a major role in postoperative functional recovery. Improved early ambulation can elicit beneficial effects in the resolution of postoperative ileus and can reduce the risk of lower extremity deep venous thrombosis. Furthermore, mobilisation might reduce pulmonary complications[170]. The risk for VTE, which is particularly high in this patient population, must be managed from the beginning of the preoperative period and continue during the entire surgical operation until the postoperative period as a result of early mobilisation and proper pharmacological thromboprophylaxis. At our University Hospital, we generally mobilise patients out of their beds for more than one hour from POD 1 and progressively increase the hours of mobilisation from POD 2. Patients who had undergone major abdominal surgery for gastrointestinal malignancies should be considered for post-discharge VTE prophylaxis for up to 4 wk following surgery during the following situations: residual or metastatic disease, obesity or previous history of VTE.

***Intensive respiratory rehabilitation***

Pulmonary complications following pancreatic resection occur in approximately one quarter of all patients[171]. Many pathophysiological modifications that occur under anaesthesia and/or following surgery can interact with each other, resulting in respiratory complications.

Reduced lung inflation is one of the basic causes of postoperative pulmonary dysfunction[172].

After upper abdominal and thoracic surgery, postoperative diaphragmatic dysfunction[173], which is the most important determinant of respiratory complications and atelectasis, is commonly observed and is caused by the mechanical compression of alveoli and the resorption of alveolar gases, which are the factors most commonly implicated in respiratory complications[174].

In recent years, breathing (deep breathing and directed cough) and chest wall physiotherapy have been introduced into clinical practice to prevent pulmonary complications. Physiotherapy includes a variety of manual treatments (postural drainage, percussion, clapping, vibration, or shaking) as well as the use of mechanical breathing devices (incentive spirometry, blow bottles, intermittent positive pressure breathing, and continuous positive airway pressure).

A systematic review showed that postoperative non-invasive ventilation, specifically continuous positive airway pressure (CPAP), improves hypoxaemia and reduces both postoperative complications and the requirement for intubation in patients undergoing abdominal surgery[170]. Furthermore, there is no specific study focusing on the role of chest physiotherapy after pancreatic resection; it is nonetheless included in the care plan at our institution. Every patient who has undergone pancreatic surgery is instructed to use a blow bottle (5 min/h) and undergoes an individualised exercise schedule that is designed by physiotherapists. Further, certain short courses of non-invasive mechanical ventilation (CPAP) can be performed as needed.

***Intensive postoperative management***

Despite continuous improvements in operative technique and perioperative management, the increasing age of patients undergoing major abdominal surgery exposes patients to an increasing number of postoperative complications, leading to increased morbidity, mortality, length of hospital stay, and hospital costs. Although the concept of fast-track surgery has questioned the traditional use of intensive care units, there is increasing evidence indicating that access to Intensive Care Units (ICUs) results in a more favourable impact on the outcomes of major abdominal surgeries.

In the case of pancreaticoduodenectomy, even high-volume centres report a major postoperative complication rate of approximately 20%[175]. Because of these observations, patients who undergo pancreatic cancer surgeries might benefit from admission to the ICU.

An ideal ICU model should involve the cooperation of the intensivists who primarily care for the patients with the primary physician and surgeon[176].

Current general concepts of fast track surgery have been implemented in intensive care units. Early mobilisation, early enteral feeding, and restrictive perioperative fluid management are generally performed at the ICUs of our institution. In addition to these programmes, ICU stays can offer extended haemodynamic monitoring, which is useful in goal-directed fluid therapy, the possibility of invasive and non-invasive ventilation, the continuous application of intravenous drugs or subsequently required extracorporeal procedures.

In summary, most patients who undergo elective pancreatic surgery for cancer do not necessary require intensive care admission, whereas high-risk patients might benefit from postoperative care in the ICUs. We suggest that surgical intensive care units play a pivotal role in the perioperative care of patients undergoing major abdominal surgeries, and patients with co-morbidities or elderly patients should be scheduled for intensive care treatment[177, 178].

**CONCLUSION**

In recent decades, diagnostic modalities and the surgical treatments of PC have significantly progressed, despite the fact that overall prognosis has only marginally changed. The management of patients affected by PC is complex and requires expertise in many fields. Multidisciplinary teams are necessary to optimise and improve the overall care and outcomes of patients. Because more patients are referred to surgery at an advanced age, a coordinated effort between surgeon and anaesthetist in terms of risk assessment is necessary, particularly for borderline resectable or unresectable disease cases (to spare the risk and cost of surgery for patients who are affected by advance disease and whose life expectancy might be potentially shortened by an unuseful and dangerous surgical operation)[179]. More favourable outcomes are attained if PC patients are appropriately referred to tertiary centres for assessment by surgical, medical and radiation oncologists, gastroenterologists, anaesthetists and other dedicated health care providers. The anaesthetist plays a key role in the preoperative assessment, intraoperative management and during the postoperative period assessment. For this reason, close cooperation between surgeons and anaesthesiologists is crucial for ensuring the safe performance of major gastrointestinal surgery with acceptable morbidity and mortality rates.

**REFERENCES**

1 **Michaud DS**. Epidemiology of pancreatic cancer. *Minerva Chir* 2004; **59**: 99-111 [PMID: 15238885]

2 **Kedra B**, Popiela T, Sierzega M, Precht A. Prognostic factors of long-term survival after resective procedures for pancreatic cancer. *Hepatogastroenterology* 2001; **48**: 1762-1766 [PMID: 11813619]

3 **Kosuri K**, Muscarella P, Bekaii-Saab TS. Updates and controversies in the treatment of pancreatic cancer. *Clin Adv Hematol Oncol* 2006; **4**: 47-54 [PMID: 16562370]

4 **Marandola M**, Cilli T, Alessandri F, Tellan G, Caronna R, Chirletti P, Delogu G. Perioperative management in patients undergoing pancreatic surgery: the anesthesiologist's point of view. *Transplant Proc* 2008; **40**: 1195-1199 [PMID: 18555147 DOI: 10.1016/j.transproceed.2008.03.114]

5 **Lynch SM**, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. *Am J Epidemiol* 2009; **170**: 403-413 [PMID: 19561064 DOI: 10.1093/aje/kwp134]

6 **Brand RE**, Greer JB, Zolotarevsky E, Brand R, Du H, Simeone D, Zisman A, Gorchow A, Lee SY, Roy HK, Anderson MA. Pancreatic cancer patients who smoke and drink are diagnosed at younger ages. *Clin Gastroenterol Hepatol* 2009; **7**: 1007-1012 [PMID: 19560558 DOI: 10.1016/j.cgh.2009.06.008]

7 **Permert J**, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. *Eur J Surg* 1993; **159**: 101-107 [PMID: 8098623]

8 **Ogren M**, Bergqvist D, Wåhlander K, Eriksson H, Sternby NH. Trousseau's syndrome - what is the evidence? A population-based autopsy study. *Thromb Haemost* 2006; **95**: 541-545 [PMID: 16525584]

9 **Sener SF**, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. *J Am Coll Surg* 1999; **189**: 1-7 [PMID: 10401733 DOI: 10.1016/S1072-7515(99)00075-7]

10 **Grade M**, Quintel M, Ghadimi BM. Standard perioperative management in gastrointestinal surgery. *Langenbecks Arch Surg* 2011; **396**: 591-606 [PMID: 21448724 DOI: 10.1007/s00423-011-0782-y]

11 **Cameron JL**, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. *Ann Surg* 2006; **244**: 10-15 [PMID: 16794383 DOI: 10.1097/01.sla.0000217673.04165.ea]

12 **Levine WC**, Mehta V, Landesberg G. Anesthesia for the elderly: selected topics. *Curr Opin Anaesthesiol* 2006; **19**: 320-324 [PMID: 16735817 DOI: 10.1097/01.aco.0000192807.63785.59]

13 **Ackland GL**, Edwards M. Defining higher-risk surgery. *Curr Opin Crit Care* 2010; **16**: 339-346 [PMID: 20489608 DOI: 10.1097/MCC.0b013e328339fad5]

14 **Copeland GP**, Jones D, Walters M. POSSUM: a scoring system for surgical audit. *Br J Surg* 1991; **78**: 355-360 [PMID: 2021856 DOI: 10.1002/bjs.1800780327]

15 **Richards CH**, Leitch FE, Horgan PG, McMillan DC. A systematic review of POSSUM and its related models as predictors of post-operative mortality and morbidity in patients undergoing surgery for colorectal cancer. *J Gastrointest Surg* 2010; **14**: 1511-1520 [PMID: 20824372 DOI: 10.1007/s11605-010-1333-5]

16 **Whiteley MS**, Prytherch DR, Higgins B, Weaver PC, Prout WG. An evaluation of the POSSUM surgical scoring system. *Br J Surg* 1996; **83**: 812-815 [PMID: 8696749 DOI: 10.1002/bjs.1800830628]

17 **Wang H**, Chen T, Wang H, Song Y, Li X, Wang J. A systematic review of the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity and its Portsmouth modification as predictors of post-operative morbidity and mortality in patients undergoing pancreatic surgery. *Am J Surg* 2013; **205**: 466-472 [PMID: 23395580 DOI: 10.1016/j.amjsurg.2012.06.011]

18 **Zhang Y**, Fu L, Zhang ZD, Li ZJ, Liu XB, Hu WM, Mai G, Yan LI, Zeng Y, Tian BL. Evaluation of POSSUM in predicting post-operative morbidity in patients undergoing pancreaticoduodenectomy. *J Int Med Res* 2009; **37**: 1859-1867 [PMID: 20146884 DOI: 10.1177/147323000903700622]

19 **Dimick JB**, Cowan JA, Upchurch GR, Colletti LM. Hospital volume and surgical outcomes for elderly patients with colorectal cancer in the United States. *J Surg Res* 2003; **114**: 50-56 [PMID: 13678698 DOI: 10.1016/S0022-4804(03)00207-5]

20 **La Torre M**, Ziparo V, Nigri G, Cavallini M, Balducci G, Ramacciato G. Malnutrition and pancreatic surgery: prevalence and outcomes. *J Surg Oncol* 2013; **107**: 702-708 [PMID: 23280557 DOI: 10.1002/jso.23304]

21 **Studley HO**. Percentage of weight loss: a basic indicator of surgical risk in patients with chronic peptic ulcer. 1936. *Nutr Hosp* 2001; **16**: 141-13; discussion 141-13; [PMID: 11680474]

22 **Fleisher LA**. Cardiac risk stratification for noncardiac surgery: update from the American College of Cardiology/American Heart Association 2007 guidelines. *Cleve Clin J Med* 2009; **76** Suppl 4: S9-15 [PMID: 19880841 DOI: 10.3949/ccjm.76.s4.02]

23 **Hollingsworth KG**, Blamire AM, Keavney BD, Macgowan GA. Left ventricular torsion, energetics, and diastolic function in normal human aging. *Am J Physiol Heart Circ Physiol* 2012; **302**: H885-H892 [PMID: 22180656 DOI: 10.1152/ajpheart.00985.2011]

24 **Nair D**, Shlipak MG, Angeja B, Liu HH, Schiller NB, Whooley MA. Association of anemia with diastolic dysfunction among patients with coronary artery disease in the Heart and Soul Study. *Am J Cardiol* 2005; **95**: 332-336 [PMID: 15670540 DOI: 10.1016/j.amjcard.2004.09.029]

25 **Filipovic M**, Wang J, Michaux I, Hunziker P, Skarvan K, Seeberger MD. Effects of halothane, sevoflurane and propofol on left ventricular diastolic function in humans during spontaneous and mechanical ventilation. *Br J Anaesth* 2005; **94**: 186-192 [PMID: 15556965 DOI: 10.1093/bja/aei028]

26 **Schmidt C**, Hinder F, Van Aken H, Theilmeier G, Bruch C, Wirtz SP, Bürkle H, Gühs T, Rothenburger M, Berendes E. The effect of high thoracic epidural anesthesia on systolic and diastolic left ventricular function in patients with coronary artery disease. *Anesth Analg* 2005; **100**: 1561-1569 [PMID: 15920175 DOI: 10.1213/01.ANE.0000154963.29271.36]

27 **Alagiakrishnan K**, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. *Ann Med* 2013; **45**: 37-50 [PMID: 22413912 DOI: 10.3109/07853890.2012.660493]

28 **Montori VM**, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schünemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: a systematic review. *JAMA* 2005; **294**: 2203-2209 [PMID: 16264162 DOI: 10.1001/jama.294.17.2203]

29 **Dunn PF**, Landesberg G. Perioperative beta-blocker therapy and mortality. *N Engl J Med* 2005; **353**: 2513-255; author reply 2513-255; [PMID: 16353302 DOI: 10.1056/NEJM200512083532319]

30 **Devereaux PJ**, Yusuf S, Yang H, Choi PT, Guyatt GH. Are the recommendations to use perioperative beta-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? *CMAJ* 2004; **171**: 245-247 [PMID: 15289423 DOI: 10.1503/cmaj.1031619]

31 **Poldermans D**, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. *Eur Heart J* 2009; **30**: 2769-2812 [PMID: 19713421 DOI: 10.1093/eurheartj/ehp337]

32 **Fleischmann KE**, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Robb JF, Valentine RJ. 2009 ACCF/AHA focused update on perioperative beta blockade. *J Am Coll Cardiol* 2009; **54**: 2102-2128 [PMID: 19926021 DOI: 10.1016/j.jacc.2009.07.004]

33 **Johnson RG**, Arozullah AM, Neumayer L, Henderson WG, Hosokawa P, Khuri SF. Multivariable predictors of postoperative respiratory failure after general and vascular surgery: results from the patient safety in surgery study. *J Am Coll Surg* 2007; **204**: 1188-1198 [PMID: 17544077 DOI: 10.1016/j.jamcollsurg.2007.02.070]

34 **Khuri SF**, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. *Ann Surg* 2005; **242**: 326-41; discussion 341-3 [PMID: 16135919]

35 **Canet J**, Gallart L, Gomar C, Paluzie G, Vallès J, Castillo J, Sabaté S, Mazo V, Briones Z, Sanchis J. Prediction of postoperative pulmonary complications in a population-based surgical cohort. *Anesthesiology* 2010; **113**: 1338-1350 [PMID: 21045639 DOI: 10.1097/ALN.0b013e3181fc6e0a]

36 **Canet J**, Gallart L. Predicting postoperative pulmonary complications in the general population. *Curr Opin Anaesthesiol* 2013; **26**: 107-115 [PMID: 23407154 DOI: 10.1097/ACO.0b013e32835e8acd]

37 **Pasquina P**, Tramèr MR, Granier JM, Walder B. Respiratory physiotherapy to prevent pulmonary complications after abdominal surgery: a systematic review. *Chest* 2006; **130**: 1887-1899 [PMID: 17167013 DOI: 10.1378/chest.130.6.1887]

38 **Squadrone V**, Coha M, Cerutti E, Schellino MM, Biolino P, Occella P, Belloni G, Vilianis G, Fiore G, Cavallo F, Ranieri VM. Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. *JAMA* 2005; **293**: 589-595 [PMID: 15687314 DOI: 10.1001/jama.293.5.589]

39 **Hemmes SN**, Severgnini P, Jaber S, Canet J, Wrigge H, Hiesmayr M, Tschernko EM, Hollmann MW, Binnekade JM, Hedenstierna G, Putensen C, de Abreu MG, Pelosi P, Schultz MJ. Rationale and study design of PROVHILO - a worldwide multicenter randomized controlled trial on protective ventilation during general anesthesia for open abdominal surgery. *Trials* 2011; **12**: 111 [PMID: 21548927 DOI: 10.1186/1745-6215-12-111]

40 **Mourão F**, Amado D, Ravasco P, Vidal PM, Camilo ME. Nutritional risk and status assessment in surgical patients: a challenge amidst plenty. *Nutr Hosp* 2004; **19**: 83-88 [PMID: 15049409]

41 **Charlson ME**, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; **40**: 373-383 [PMID: 3558716 DOI: 10.1016/0021-9681(87)90171-8]

42 **La Torre M**, Velluti F, Giuliani G, Di Giulio E, Ziparo V, La Torre F. Promptness of diagnosis is the main prognostic factor after colonoscopic perforation. *Colorectal Dis* 2012; **14**: e23-e26 [PMID: 21831176 DOI: 10.1111/j.1463-1318.2011.02755.x]

43 **O'Flynn J**, Peake H, Hickson M, Foster D, Frost G. The prevalence of malnutrition in hospitals can be reduced: results from three consecutive cross-sectional studies. *Clin Nutr* 2005; **24**: 1078-1088 [PMID: 16219393 DOI: 10.1016/j.clnu.2005.08.012]

44 **White JV**, Guenter P, Jensen G, Malone A, Schofield M. Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *J Acad Nutr Diet* 2012; **112**: 730-738 [PMID: 22709779 DOI: 10.1016/j.jand.2012.03.012]

45 **White JV**, Guenter P, Jensen G, Malone A, Schofield M. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *JPEN J Parenter Enteral Nutr* 2012; **36**: 275-283 [PMID: 22535923 DOI: 10.1177/0148607112440285]

46 **Cooper C**, Brierley ER, Burden ST. Improving adherence to a care plan generated from the Malnutrition Universal Screening Tool. *Eur J Clin Nutr* 2013; **67**: 174-179 [PMID: 23232583 DOI: 10.1038/ejcn.2012.196]

47 **Stratton RJ**, Hackston A, Longmore D, Dixon R, Price S, Stroud M, King C, Elia M. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. *Br J Nutr* 2004; **92**: 799-808 [PMID: 15533269 DOI: 10.1079/BJN20041258]

48 **Kehlet H**. Multimodal approach to control postoperative pathophysiology and rehabilitation. *Br J Anaesth* 1997; **78**: 606-617 [PMID: 9175983 DOI: 10.1093/bja/78.5.606]

49 **Lassen K**, Soop M, Nygren J, Cox PB, Hendry PO, Spies C, von Meyenfeldt MF, Fearon KC, Revhaug A, Norderval S, Ljungqvist O, Lobo DN, Dejong CH. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. *Arch Surg* 2009; **144**: 961-969 [PMID: 19841366 DOI: 10.1001/archsurg.2009.170]

50 **Balzano G**, Zerbi A, Braga M, Rocchetti S, Beneduce AA, Di Carlo V. Fast-track recovery programme after pancreatico- duodenectomy reduces delayed gastric emptying. *Br J Surg* 2008; **95**: 1387-1393 [PMID: 18844251 DOI: 10.1002/bjs.6324]

51 **Lavu H**, Kennedy EP, Mazo R, Stewart RJ, Greenleaf C, Grenda DR, Sauter PK, Leiby BE, Croker SP, Yeo CJ. Preoperative mechanical bowel preparation does not offer a benefit for patients who undergo pancreaticoduodenectomy. *Surgery* 2010; **148**: 278-284 [PMID: 20447669 DOI: 10.1016/j.surg.2010.03.012]

52 **Salvia R**, Malleo G, Butturini G, Dal Molin M, Esposito A, Marchegiani G, Paiella S, Malpaga A, Fontana M, Personi B, Bassi C. Perioperative management of patients undergoing pancreatic resection: implementation of a care plan in a tertiary-care center. *J Surg Oncol* 2013; **107**: 51-57 [PMID: 23129003 DOI: 10.1002/jso.23285]

53 **Spelt L**, Ansari D, Sturesson C, Tingstedt B, Andersson R. Fast-track programmes for hepatopancreatic resections: where do we stand? *HPB (Oxford)* 2011; **13**: 833-838 [PMID: 22081917 DOI: 10.1111/j.1477-2574.2011.00391.x]

54 **Berberat PO**, Ingold H, Gulbinas A, Kleeff J, Müller MW, Gutt C, Weigand M, Friess H, Büchler MW. Fast track--different implications in pancreatic surgery. *J Gastrointest Surg* 2007; **11**: 880-887 [PMID: 17440787 DOI: 10.1007/s11605-007-0167-2]

55 **di Sebastiano P**, Festa L, De Bonis A, Ciuffreda A, Valvano MR, Andriulli A, di Mola FF. A modified fast-track program for pancreatic surgery: a prospective single-center experience. *Langenbecks Arch Surg* 2011; **396**: 345-351 [PMID: 20703500 DOI: 10.1007/s00423-010-0707-1]

56 **Schmidt CM**, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, Baumgardner JA, Cummings OW, Jacobson LE, Broadie TA, Canal DF, Goulet RJ, Curie EA, Cardenes H, Watkins JM, Loehrer PJ, Lillemoe KD, Madura JA. Pancreaticoduodenectomy: a 20-year experience in 516 patients. *Arch Surg* 2004; **139**: 718-25; discussion 725-7 [PMID: 15249403]

57 **Gould MK**, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e227S-e277S [PMID: 22315263]

58 **Khorana AA**, Fine RL. Pancreatic cancer and thromboembolic disease. *Lancet Oncol* 2004; **5**: 655-663 [PMID: 15522652 DOI: 10.1016/S1470-2045(04)01606-7]

59 **Caprini JA**, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. *Semin Thromb Hemost* 1991; **17** Suppl 3: 304-312 [PMID: 1754886]

60 **Bozzato S**, Galli L, Ageno W. Thromboprophylaxis in surgical and medical patients. *Semin Respir Crit Care Med* 2012; **33**: 163-175 [PMID: 22648489 DOI: 10.1055/s-0032-1311795]

61 **Bergqvist D**, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med* 2002; **346**: 975-980 [PMID: 11919306 DOI: 10.1056/NEJMoa012385]

62 **Douketis JD**, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e326S-e350S [PMID: 22315266]

63 **Carli F**, Kehlet H, Baldini G, Steel A, McRae K, Slinger P, Hemmerling T, Salinas F, Neal JM. Evidence basis for regional anesthesia in multidisciplinary fast-track surgical care pathways. *Reg Anesth Pain Med* 2011; **36**: 63-72 [PMID: 22002193 DOI: 10.1097/AAP.0b013e31820307f7]

64 **Clemente A**, Carli F. The physiological effects of thoracic epidural anesthesia and analgesia on the cardiovascular, respiratory and gastrointestinal systems. *Minerva Anestesiol* 2008; **74**: 549-563 [PMID: 18854796]

65 **Treschan TA**, Taguchi A, Ali SZ, Sharma N, Kabon B, Sessler DI, Kurz A. The effects of epidural and general anesthesia on tissue oxygenation. *Anesth Analg* 2003; **96**: 1553-157, table of contents [PMID: 12760974 DOI: 10.1213/01.ANE.0000063824.43113.DB]

66 **Kabon B**, Fleischmann E, Treschan T, Taguchi A, Kapral S, Kurz A. Thoracic epidural anesthesia increases tissue oxygenation during major abdominal surgery. *Anesth Analg* 2003; **97**: 1812-1817 [PMID: 14633566 DOI: 10.1213/01.ANE.0000087040.48267.54]

67 **Moraca RJ**, Sheldon DG, Thirlby RC. The role of epidural anesthesia and analgesia in surgical practice. *Ann Surg* 2003; **238**: 663-673 [PMID: 14578727 DOI: 10.1097/01.sla.0000094300.36689.ad]

68 **Snyder GL**, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. *Br J Anaesth* 2010; **105**: 106-115 [PMID: 20627881 DOI: 10.1093/bja/aeq164]

69 **Gottschalk A**, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. *Anesthesiology* 2010; **113**: 27-34 [PMID: 20508494 DOI: 10.1097/ALN.0b013e3181de6d0d]

70 National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. *Am J Infect Control* 1996; **24**: 380-388 [PMID: 8902113 DOI: 10.1016/S0196-6553(96)90026-7]

71 **Mauermann WJ**, Nemergut EC. The anesthesiologist's role in the prevention of surgical site infections. *Anesthesiology* 2006; **105**: 413-21; quiz 439-40 [PMID: 16871076 DOI: 10.1097/00000542-200608000-00025]

72 **Anderson DJ**, Kaye KS, Classen D, Arias KM, Podgorny K, Burstin H, Calfee DP, Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Klompas M, Lo E, Marschall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Saint S, Salgado CD, Weinstein RA, Wise R, Yokoe DS. Strategies to prevent surgical site infections in acute care hospitals. *Infect Control Hosp Epidemiol* 2008; **29** Suppl 1: S51-S61 [PMID: 18840089 DOI: 10.1086/591064]

73 **Haynes AB**, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, Herbosa T, Joseph S, Kibatala PL, Lapitan MC, Merry AF, Moorthy K, Reznick RK, Taylor B, Gawande AA. A surgical safety checklist to reduce morbidity and mortality in a global population. *N Engl J Med* 2009; **360**: 491-499 [PMID: 19144931 DOI: 10.1056/NEJMsa0810119]

74 **de Vries EN**, Prins HA, Crolla RM, den Outer AJ, van Andel G, van Helden SH, Schlack WS, van Putten MA, Gouma DJ, Dijkgraaf MG, Smorenburg SM, Boermeester MA. Effect of a comprehensive surgical safety system on patient outcomes. *N Engl J Med* 2010; **363**: 1928-1937 [PMID: 21067384 DOI: 10.1056/NEJMsa0911535]

75 **Polk HC**, Lopez-Mayor JF. Postoperative wound infection: a prospective study of determinant factors and prevention. *Surgery* 1969; **66**: 97-103 [PMID: 4892316]

76 **Diana M**, Hübner M, Eisenring MC, Zanetti G, Troillet N, Demartines N. Measures to prevent surgical site infections: what surgeons (should) do. *World J Surg* 2011; **35**: 280-288 [PMID: 21088838 DOI: 10.1007/s00268-010-0862-0]

77 **Mangram AJ**, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999; **20**: 250-78; quiz 279-80 [PMID: 10219875 DOI: 10.1086/501620]

78 ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. *Am J Health Syst Pharm* 1999; **56**: 1839-1888 [PMID: 10511234]

79 **Kurz A**, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. *N Engl J Med* 1996; **334**: 1209-1215 [PMID: 8606715 DOI: 10.1056/NEJM199605093341901]

80 **Sessler DI**. Complications and treatment of mild hypothermia. *Anesthesiology* 2001; **95**: 531-543 [PMID: 11506130 DOI: 10.1097/00000542-200108000-00040]

81 **Sessler DI**, Akça O. Nonpharmacological prevention of surgical wound infections. *Clin Infect Dis* 2002; **35**: 1397-1404 [PMID: 12439804 DOI: 10.1086/344275]

82 **Hopf HW**, Hunt TK, West JM, Blomquist P, Goodson WH, Jensen JA, Jonsson K, Paty PB, Rabkin JM, Upton RA, von Smitten K, Whitney JD. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. *Arch Surg* 1997; **132**: 997-1004; discussion 1005 [PMID: 9301613 DOI: 10.1001/archsurg.1997.01430330063010]

83 **Bräuer A**, Quintel M. Forced-air warming: technology, physical background and practical aspects. *Curr Opin Anaesthesiol* 2009; **22**: 769-774 [PMID: 19734783 DOI: 10.1097/ACO.0b013e328331d134]

84 **Bräuer A**, Bovenschulte H, Perl T, Zink W, English MJ, Quintel M. What determines the efficacy of forced-air warming systems? A manikin evaluation with upper body blankets. *Anesth Analg* 2009; **108**: 192-198 [PMID: 19095849 DOI: 10.1213/ane.0b013e31818e0cee]

85 **Capes SE**, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 2000; **355**: 773-778 [PMID: 10711923 DOI: 10.1016/S0140-6736(99)08415-9]

86 **Cheadle WG**. Risk factors for surgical site infection. *Surg Infect (Larchmt)* 2006; **7** Suppl 1: S7-11 [PMID: 16834549 DOI: 10.1089/sur.2006.7.s1-7]

87 **van den Berghe G**, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001; **345**: 1359-1367 [PMID: 11794168 DOI: 10.1056/NEJMoa011300]

88 **Brunkhorst FM**, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008; **358**: 125-139 [PMID: 18184958 DOI: 10.1056/NEJMoa070716]

89 **Finfer S**, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; **360**: 1283-1297 [PMID: 19318384 DOI: 10.1056/NEJMoa0810625]

90 **Kersten JR**, Warltier DC, Pagel PS. Aggressive control of intraoperative blood glucose concentration: a shifting paradigm? *Anesthesiology* 2005; **103**: 677-678 [PMID: 16192757 DOI: 10.1097/00000542-200510000-00002]

91 **Tartter PI**, Quintero S, Barron DM. Perioperative blood transfusion associated with infectious complications after colorectal cancer operations. *Am J Surg* 1986; **152**: 479-482 [PMID: 3777324 DOI: 10.1016/0002-9610(86)90207-2]

92 **Raghavan M**, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. *Chest* 2005; **127**: 295-307 [PMID: 15653997 DOI: 10.1378/chest.127.1.295]

93 **Carson JL**, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. *Transfusion* 2002; **42**: 812-818 [PMID: 12375651 DOI: 10.1046/j.1537-2995.2002.00123.x]

94 **Carson JL**, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, Noveck H, Strom BL. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. *Lancet* 1996; **348**: 1055-1060 [PMID: 8874456 DOI: 10.1016/S0140-6736(96)04330-9]

95 **Hébert PC**, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? *Crit Care Med* 2001; **29**: 227-234 [PMID: 11246298 DOI: 10.1097/00003246-200102000-00001]

96 **Goodnough LT**, Levy JH, Murphy MF. Concepts of blood transfusion in adults. *Lancet* 2013; **381**: 1845-1854 [PMID: 23706801 DOI: 10.1016/S0140-6736(13)60650-9]

97 **Shander A**, Fink A, Javidroozi M, Erhard J, Farmer SL, Corwin H, Goodnough LT, Hofmann A, Isbister J, Ozawa S, Spahn DR. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. *Transfus Med Rev* 2011; **25**: 232-246.e53 [PMID: 21498040]

98 Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. *Anesthesiology* 2006; **105**: 198-208 [PMID: 16810012 DOI: 10.1097/00000542-200607000-00030]

99 **Carson JL**, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B. Red blood cell transfusion: a clinical practice guideline from the AABB\*. *Ann Intern Med* 2012; **157**: 49-58 [PMID: 22751760 DOI: 10.7326/0003-4819-157-1-201206190-00429]

100 **Kozek-Langenecker SA**, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, Görlinger K, Haas T, Imberger G, Jacob M, Lancé M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, Wikkelsø AJ, Wouters P, Wyffels P. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2013; **30**: 270-382 [PMID: 23656742 DOI: 10.1097/EJA.0b013e32835f4d5b]

101 **Chappell D**, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. A rational approach to perioperative fluid management. *Anesthesiology* 2008; **109**: 723-740 [PMID: 18813052 DOI: 10.1097/ALN.0b013e3181863117]

102 **Futier E**, Constantin JM, Petit A, Chanques G, Kwiatkowski F, Flamein R, Slim K, Sapin V, Jaber S, Bazin JE. Conservative vs restrictive individualized goal-directed fluid replacement strategy in major abdominal surgery: A prospective randomized trial. *Arch Surg* 2010; **145**: 1193-1200 [PMID: 21173294 DOI: 10.1001/archsurg.2010.275]

103 **Jacob M**, Chappell D, Rehm M. Clinical update: perioperative fluid management. *Lancet* 2007; **369**: 1984-1986 [PMID: 17574081 DOI: 10.1016/S0140-6736(07)60926-X]

104 **Lobo DN**, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. *Lancet* 2002; **359**: 1812-1818 [PMID: 12044376 DOI: 10.1016/S0140-6736(02)08711-1]

105 **Holte K**, Sharrock NE, Kehlet H. Pathophysiology and clinical implications of perioperative fluid excess. *Br J Anaesth* 2002; **89**: 622-632 [PMID: 12393365 DOI: 10.1093/bja/aef220]

106 **Gurgel ST**, do Nascimento P. Maintaining tissue perfusion in high-risk surgical patients: a systematic review of randomized clinical trials. *Anesth Analg* 2011; **112**: 1384-1391 [PMID: 21156979 DOI: 10.1213/ANE.0b013e3182055384]

107 **Baron JF**, De Kegel D, Prost AC, Mundler O, Arthaud M, Basset G, Maistre G, Masson F, Carayon A, Landault C. Low molecular weight hydroxyethyl starch 6% compared to albumin 4% during intentional hemodilution. *Intensive Care Med* 1991; **17**: 141-148 [PMID: 1712801 DOI: 10.1007/BF01704717]

108 **Nisanevich V**, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I. Effect of intraoperative fluid management on outcome after intraabdominal surgery. *Anesthesiology* 2005; **103**: 25-32 [PMID: 15983453 DOI: 10.1097/00000542-200507000-00008]

109 **Joshi GP**. Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery. *Anesth Analg* 2005; **101**: 601-605 [PMID: 16037184 DOI: 10.1213/01.ANE.0000159171.26521.31]

110 **MacKay G**, Fearon K, McConnachie A, Serpell MG, Molloy RG, O'Dwyer PJ. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery. *Br J Surg* 2006; **93**: 1469-1474 [PMID: 17078116 DOI: 10.1002/bjs.5593]

111 **Holte K**, Foss NB, Andersen J, Valentiner L, Lund C, Bie P, Kehlet H. Liberal or restrictive fluid administration in fast-track colonic surgery: a randomized, double-blind study. *Br J Anaesth* 2007; **99**: 500-508 [PMID: 17681972 DOI: 10.1093/bja/aem211]

112 **Kimberger O**, Arnberger M, Brandt S, Plock J, Sigurdsson GH, Kurz A, Hiltebrand L. Goal-directed colloid administration improves the microcirculation of healthy and perianastomotic colon. *Anesthesiology* 2009; **110**: 496-504 [PMID: 19225390 DOI: 10.1097/ALN.0b013e31819841f6]

113 **Hamilton MA**, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. *Anesth Analg* 2011; **112**: 1392-1402 [PMID: 20966436 DOI: 10.1213/ANE.0b013e3181eeaae5]

114 **Marik PE**, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. *Chest* 2008; **134**: 172-178 [PMID: 18628220 DOI: 10.1378/chest.07-2331]

115 **Peng ZY**, Kellum JA. Perioperative fluids: a clear road ahead? *Curr Opin Crit Care* 2013; **19**: 353-358 [PMID: 23817030 DOI: 10.1097/MCC.0b013e3283632f1f]

116 **Wakeling HG**, McFall MR, Jenkins CS, Woods WG, Miles WF, Barclay GR, Fleming SC. Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. *Br J Anaesth* 2005; **95**: 634-642 [PMID: 16155038 DOI: 10.1093/bja/aei223]

117 **Bundgaard-Nielsen M**, Holte K, Secher NH, Kehlet H. Monitoring of peri-operative fluid administration by individualized goal-directed therapy. *Acta Anaesthesiol Scand* 2007; **51**: 331-340 [PMID: 17390421 DOI: 10.1111/j.1399-6576.2006.01221.x]

118 **Marik PE**, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. *Crit Care Med* 2009; **37**: 2642-2647 [PMID: 19602972 DOI: 10.1097/CCM.0b013e3181a590da]

119 **Lamke LO**, Nilsson GE, Reithner HL. Water loss by evaporation from the abdominal cavity during surgery. *Acta Chir Scand* 1977; **143**: 279-284 [PMID: 596094]

120 **Chappell D**, Westphal M, Jacob M. The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness. *Curr Opin Anaesthesiol* 2009; **22**: 155-162 [PMID: 19307890 DOI: 10.1097/ACO.0b013e328328d1b6]

121 **De Backer D**, Donadello K, Taccone FS, Ospina-Tascon G, Salgado D, Vincent JL. Microcirculatory alterations: potential mechanisms and implications for therapy. *Ann Intensive Care* 2011; **1**: 27 [PMID: 21906380 DOI: 10.1186/2110-5820-1-27]

122 **Perner A**, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med* 2012; **367**: 124-134 [PMID: 22738085 DOI: 10.1056/NEJMoa1204242]

123 **Myburgh JA**, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med* 2012; **367**: 1901-1911 [PMID: 23075127 DOI: 10.1056/NEJMoa1209759]

124 **Lobo SM**, Mendes CL, Rezende E, Dias FS. Optimizing perioperative hemodynamics: what is new? *Curr Opin Crit Care* 2013; **19**: 346-352 [PMID: 23817029 DOI: 10.1097/MCC.0b013e3283632ef1]

125 **Holte K**, Foss NB, Svensén C, Lund C, Madsen JL, Kehlet H. Epidural anesthesia, hypotension, and changes in intravascular volume. *Anesthesiology* 2004; **100**: 281-286 [PMID: 14739801 DOI: 10.1097/00000542-200402000-00016]

126 **Hedenstierna G**, Edmark L. The effects of anesthesia and muscle paralysis on the respiratory system. *Intensive Care Med* 2005; **31**: 1327-1335 [PMID: 16132894 DOI: 10.1007/s00134-005-2761-7]

127 **Reinius H**, Jonsson L, Gustafsson S, Sundbom M, Duvernoy O, Pelosi P, Hedenstierna G, Fredén F. Prevention of atelectasis in morbidly obese patients during general anesthesia and paralysis: a computerized tomography study. *Anesthesiology* 2009; **111**: 979-987 [PMID: 19809292 DOI: 10.1097/ALN.0b013e3181b87edb]

128 **Choi G**, Wolthuis EK, Bresser P, Levi M, van der Poll T, Dzoljic M, Vroom MB, Schultz MJ. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. *Anesthesiology* 2006; **105**: 689-695 [PMID: 17006066 DOI: 10.1097/00000542-200610000-00013]

129 **Wolthuis EK**, Choi G, Dessing MC, Bresser P, Lutter R, Dzoljic M, van der Poll T, Vroom MB, Hollmann M, Schultz MJ. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents pulmonary inflammation in patients without preexisting lung injury. *Anesthesiology* 2008; **108**: 46-54 [PMID: 18156881 DOI: 10.1097/01.anes.0000296068.80921.10]

130 **Sundar S**, Novack V, Jervis K, Bender SP, Lerner A, Panzica P, Mahmood F, Malhotra A, Talmor D. Influence of low tidal volume ventilation on time to extubation in cardiac surgical patients. *Anesthesiology* 2011; **114**: 1102-1110 [PMID: 21430518 DOI: 10.1097/ALN.0b013e318215e254]

131 **Talab HF**, Zabani IA, Abdelrahman HS, Bukhari WL, Mamoun I, Ashour MA, Sadeq BB, El Sayed SI. Intraoperative ventilatory strategies for prevention of pulmonary atelectasis in obese patients undergoing laparoscopic bariatric surgery. *Anesth Analg* 2009; **109**: 1511-1516 [PMID: 19843790 DOI: 10.1213/ANE.0b013e3181ba7945]

132 **Severgnini P**, Selmo G, Lanza C, Chiesa A, Frigerio A, Bacuzzi A, Dionigi G, Novario R, Gregoretti C, de Abreu MG, Schultz MJ, Jaber S, Futier E, Chiaranda M, Pelosi P. Protective mechanical ventilation during general anesthesia for open abdominal surgery improves postoperative pulmonary function. *Anesthesiology* 2013; **118**: 1307-1321 [PMID: 23542800 DOI: 10.1097/ALN.0b013e31829102de]

133 **McCrath DJ**, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. *Anesth Analg* 2005; **100**: 1576-1583 [PMID: 15920177 DOI: 10.1213/01.ANE.0000155290.86795.12]

134 **Kashuk JL**, Moore EE, Sabel A, Barnett C, Haenel J, Le T, Pezold M, Lawrence J, Biffl WL, Cothren CC, Johnson JL. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. *Surgery* 2009; **146**: 764-72; discussion 772-4 [PMID: 19789037]

135 **Kehlet H**. Labat lecture 2005: surgical stress and postoperative outcome-from here to where? *Reg Anesth Pain Med* ; **31**: 47-52 [PMID: 16418025]

136 **Kennedy EP**, Rosato EL, Sauter PK, Rosenberg LM, Doria C, Marino IR, Chojnacki KA, Berger AC, Yeo CJ. Initiation of a critical pathway for pancreaticoduodenectomy at an academic institution--the first step in multidisciplinary team building. *J Am Coll Surg* 2007; **204**: 917-23; discussion 923-4 [PMID: 17481510]

137 **Nelson R**, Tse B, Edwards S. Systematic review of prophylactic nasogastric decompression after abdominal operations. *Br J Surg* 2005; **92**: 673-680 [PMID: 15912492 DOI: 10.1002/bjs.5090]

138 **Ypsilantis E**, Praseedom RK. Current status of fast-track recovery pathways in pancreatic surgery. *JOP* 2009; **10**: 646-650 [PMID: 19890186]

139 **Choi YY**, Kim J, Seo D, Choi D, Kim MJ, Kim JH, Lee KJ, Hur KY. Is routine nasogastric tube insertion necessary in pancreaticoduodenectomy? *J Korean Surg Soc* 2011; **81**: 257-262 [PMID: 22111081]

140 **Fisher WE**, Hodges SE, Cruz G, Artinyan A, Silberfein EJ, Ahern CH, Jo E, Brunicardi FC. Routine nasogastric suction may be unnecessary after a pancreatic resection. *HPB (Oxford)* 2011; **13**: 792-796 [PMID: 21999592]

141 **Monson JR**, Guillou PJ, Keane FB, Tanner WA, Brennan TG. Cholecystectomy is safer without drainage: the results of a prospective, randomized clinical trial. *Surgery* 1991; **109**: 740-746 [PMID: 2042093]

142 **Sagar PM**, Couse N, Kerin M, May J, MacFie J. Randomized trial of drainage of colorectal anastomosis. *Br J Surg* 1993; **80**: 769-771 [PMID: 8330173 DOI: 10.1002/bjs.1800800640]

143 **Fong Y**, Brennan MF, Brown K, Heffernan N, Blumgart LH. Drainage is unnecessary after elective liver resection. *Am J Surg* 1996; **171**: 158-162 [PMID: 8554132 DOI: 10.1016/S0002-9610(99)80092-0]

144 **Fuks D**, Piessen G, Huet E, Tavernier M, Zerbib P, Michot F, Scotte M, Triboulet JP, Mariette C, Chiche L, Salame E, Segol P, Pruvot FR, Mauvais F, Roman H, Verhaeghe P, Regimbeau JM. Life-threatening postoperative pancreatic fistula (grade C) after pancreaticoduodenectomy: incidence, prognosis, and risk factors. *Am J Surg* 2009; **197**: 702-709 [PMID: 18778804 DOI: 10.1016/j.amjsurg.2008.03.004]

145 **Adham M**, Chopin-Laly X, Lepilliez V, Gincul R, Valette PJ, Ponchon T. Pancreatic resection: drain or no drain? *Surgery* 2013; **154**: 1069-1077 [PMID: 23876363 DOI: 10.1016/j.surg.2013.04.017]

146 **Kaminsky PM**, Mezhir JJ. Intraperitoneal drainage after pancreatic resection: a review of the evidence. *J Surg Res* 2013; **184**: 925-930 [PMID: 23866787 DOI: 10.1016/j.jss.2013.05.092]

147 **Lewis SJ**, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. *BMJ* 2001; **323**: 773-776 [PMID: 11588077 DOI: 10.1136/bmj.323.7316.773]

148 **Diks J**, van Hoorn DE, Nijveldt RJ, Boelens PG, Hofman Z, Bouritius H, van Norren K, van Leeuwen PA. Preoperative fasting: an outdated concept? *JPEN J Parenter Enteral Nutr* 2005; **29**: 298-304 [PMID: 15961687 DOI: 10.1177/0148607105029004298]

149 **Moore FA**, Feliciano DV, Andrassy RJ, McArdle AH, Booth FV, Morgenstein-Wagner TB, Kellum JM, Welling RE, Moore EE. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. *Ann Surg* 1992; **216**: 172-183 [PMID: 1386982 DOI: 10.1097/00000658-199208000-00008]

150 **Gerritsen A**, Besselink MG, Gouma DJ, Steenhagen E, Borel Rinkes IH, Molenaar IQ. Systematic review of five feeding routes after pancreatoduodenectomy. *Br J Surg* 2013; **100**: 589-98; discussion 599 [PMID: 23354970]

151 **Slezak LA**, Andersen DK. Pancreatic resection: effects on glucose metabolism. *World J Surg* 2001; **25**: 452-460 [PMID: 11344398 DOI: 10.1007/s002680020337]

152 **Nosadini R**, del Prato S, Tiengo A, Duner E, Toffolo G, Cobelli C, Faronato PP, Moghetti P, Muggeo M. Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. *Diabetes* 1982; **31**: 346-355 [PMID: 6759250 DOI: 10.2337/diab.31.4.346]

153 **Duron F**, Duron JJ. [Pancreatectomy and diabetes]. *Ann Chir* 1999; **53**: 406-411 [PMID: 10389330]

154 **Dresler CM**, Fortner JG, McDermott K, Bajorunas DR. Metabolic consequences of (regional) total pancreatectomy. *Ann Surg* 1991; **214**: 131-140 [PMID: 1867520 DOI: 10.1097/00000658-199108000-00007]

155 **Jethwa P**, Sodergren M, Lala A, Webber J, Buckels JA, Bramhall SR, Mirza DF. Diabetic control after total pancreatectomy. *Dig Liver Dis* 2006; **38**: 415-419 [PMID: 16527551 DOI: 10.1016/j.dld.2006.01.022]

156 **Heidt DG**, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. *J Gastrointest Surg* 2007; **11**: 209-216 [PMID: 17390175 DOI: 10.1007/s11605-006-0025-7]

157 **Van den Berghe G**. Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l. *Diabetologia* 2008; **51**: 911-915 [PMID: 18040662 DOI: 10.1007/s00125-007-0878-7]

158 **Alfonso A**, Koops MK, Mong DP, Vigersky RA. Glycemic control with regular versus lispro insulin sliding scales in hospitalized Type 2 diabetics. *J Diabetes Complications* 2006; **20**: 153-157 [PMID: 16632234 DOI: 10.1016/j.jdiacomp.2005.06.009]

159 **Okabayashi T**, Nishimori I, Yamashita K, Sugimoto T, Maeda H, Yatabe T, Kohsaki T, Kobayashi M, Hanazaki K. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. *Arch Surg* 2009; **144**: 933-937 [PMID: 19841361 DOI: 10.1001/archsurg.2009.176]

160 **Hanazaki K**. Tight glycemic control using an artificial endocrine pancreas may play an important role in preventing infection after pancreatic resection. *World J Gastroenterol* 2012; **18**: 3787-3789 [PMID: 22876028 DOI: 10.3748/wjg.v18.i29.3787]

161 **Jamil LH**, Chindris AM, Gill KR, Scimeca D, Stauffer JA, Heckman MG, Meek SE, Nguyen JH, Asbun HJ, Raimondo M, Woodward TA, Wallace MB. Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: an exploratory study. *HPB Surg* 2012; **2012**: 381328 [PMID: 22966212]

162 **Ballantyne JC**, Carr DB, deFerranti S, Suarez T, Lau J, Chalmers TC, Angelillo IF, Mosteller F. The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized, controlled trials. *Anesth Analg* 1998; **86**: 598-612 [PMID: 9495424]

163 **Kehlet H**. Postoperative ileus--an update on preventive techniques. *Nat Clin Pract Gastroenterol Hepatol* 2008; **5**: 552-558 [PMID: 18695704 DOI: 10.1038/ncpgasthep1230]

164 **White PF**. Multimodal analgesia: its role in preventing postoperative pain. *Curr Opin Investig Drugs* 2008; **9**: 76-82 [PMID: 18183534]

165 **Holte K**, Kehlet H. Effect of postoperative epidural analgesia on surgical outcome. *Minerva Anestesiol* 2002; **68**: 157-161 [PMID: 12024074]

166 **Uchida I**, Asoh T, Shirasaka C, Tsuji H. Effect of epidural analgesia on postoperative insulin resistance as evaluated by insulin clamp technique. *Br J Surg* 1988; **75**: 557-562 [PMID: 3293693 DOI: 10.1002/bjs.1800750618]

167 **Rodgers A**, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ* 2000; **321**: 1493 [PMID: 11118174 DOI: 10.1136/bmj.321.7275.1493]

168 **Steinbrook RA**. Epidural anesthesia and gastrointestinal motility. *Anesth Analg* 1998; **86**: 837-844 [PMID: 9539611]

169 **Liu SS**, Carpenter RL, Mackey DC, Thirlby RC, Rupp SM, Shine TS, Feinglass NG, Metzger PP, Fulmer JT, Smith SL. Effects of perioperative analgesic technique on rate of recovery after colon surgery. *Anesthesiology* 1995; **83**: 757-765 [PMID: 7574055 DOI: 10.1097/00000542-199510000-00015]

170 **Haines KJ**, Skinner EH, Berney S. Association of postoperative pulmonary complications with delayed mobilisation following major abdominal surgery: an observational cohort study. *Physiotherapy* 2013; **99**: 119-125 [PMID: 23219632]

171 **Manzano RM**, Carvalho CR, Saraiva-Romanholo BM, Vieira JE. Chest physiotherapy during immediate postoperative period among patients undergoing upper abdominal surgery: randomized clinical trial. *Sao Paulo Med J* 2008; **126**: 269-273 [PMID: 19099160 DOI: 10.1590/S1516-31802008000500005]

172 **Chawla G**, Drummond GB. Fentanyl decreases end-expiratory lung volume in patients anaesthetized with sevoflurane. *Br J Anaesth* 2008; **100**: 411-414 [PMID: 18216033 DOI: 10.1093/bja/aem376]

173 **Warner DO**. Preventing postoperative pulmonary complications: the role of the anesthesiologist. *Anesthesiology* 2000; **92**: 1467-1472 [PMID: 10781293 DOI: 10.1097/00000542-200005000-00037]

174 **Duggan M**, McNamara PJ, Engelberts D, Pace-Asciak C, Babyn P, Post M, Kavanagh BP. Oxygen attenuates atelectasis-induced injury in the in vivo rat lung. *Anesthesiology* 2005; **103**: 522-531 [PMID: 16129977 DOI: 10.1097/00000542-200509000-00015]

175 **Witkowski ER**, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. *J Surg Oncol* 2013; **107**: 97-103 [PMID: 22991309 DOI: 10.1002/jso.23267]

176 **Shapiro MJ**. Where have all the surgical intensivists gone? *Crit Care Med* 2006; **34**: 2485-2486 [PMID: 16921318 DOI: 10.1097/01.CCM.0000234657.74127.36]

177 **Aguilar-Nascimento JE**, Salomão AB, Caporossi C, Diniz BN. Clinical benefits after the implementation of a multimodal perioperative protocol in elderly patients. *Arq Gastroenterol* 2010; **47**: 178-183 [PMID: 20721464 DOI: 10.1590/S0004-28032010000200012]

178 **Ghaferi AA**, Osborne NH, Birkmeyer JD, Dimick JB. Hospital characteristics associated with failure to rescue from complications after pancreatectomy. *J Am Coll Surg* 2010; **211**: 325-330 [PMID: 20800188 DOI: 10.1016/j.jamcollsurg.2010.04.025]

179 **Takhar AS**, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. *BMJ* 2004; **329**: 668-673 [PMID: 15374918 DOI: 10.1136/bmj.329.7467.668]

**P-Reviewers:** Hartwig W, Tang Y **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

**Table 1** **A schematic representation of the integrated management of perioperative patients undergoing surgery for pancreatic cancer**

|  |  |  |
| --- | --- | --- |
| **Preoperative** | **Intraoperative** | **Postoperative** |
| Informed patient consent | Combined general and epidural analgesia | Early nasogastric tube, catheter and drain removal |
| Preoperative risk assessment | Prevention of surgical site infection (SSIs):Antimicrobial prophylaxisAvoid hypothermiaGlucose control | Early oral nutrition/glycaemic control/goal-directed fluid therapy |
| Pain relief/non-opioid oral analgesia |
| Evaluation and optimisation of preoperative physical conditions and medications | Blood transfusion management | Intensive postoperative ambulation and prevention of venous thromboembolism |
| Nutritional status  | Fluid management | Intensive respiratory rehabilitation |
| Risk Stratification, Rationale for Thromboprophylaxis, and Recommendations | Optimisation of intraoperative ventilation | Intensive postoperative management |
|  | Intraoperative thromboprophylaxis |  |

Modified from Grade *et al*[12].

**Table 2 Perioperative clinical predictors of postoperative pulmonary complication in pancreatic oncological surgery**

|  |  |  |
| --- | --- | --- |
| **Patient-related factors** | **Surgery-related factors** | **Preoperative testing-related factors** |
| Congestive heart failure | Abdominal surgery | Serum albumin concentration <2.5 g/dL |
| ASA score>2 | Surgery duration >3 h | Anaemia (Hb<10 g/dL) |
| Age> 65 yr | General anaesthesia | Low SpO2 |
| chronic obstructive pulmonary disease | Transfusions | Chest X ray |
| Functional dependence | Prolonged hospitalisation |  |
| Weight loss |  |  |
| Impaired sensorium |  |  |
| Cigarette smoking |  |  |
| Respiratory infections within the past month |  |  |

**Table 3 Guidelines on the prophylaxis of venous thromboembolism and antiplatelet and anticoagulant management adjusted according to recent guidelines**

|  |
| --- |
| In patients receiving bridging anticoagulation with a therapeutic-dose IV of unfractionated heparin, treatment is recommended to be stopped no later than at 4 to 6 h prior to surgery. |
| In patients receiving bridging anticoagulation with a therapeutic-dose of LMWH, the last preoperative dose of LMWH is recommended to be administered at approximately 24 h prior to surgery instead of at 12 h prior to surgery. |
| In patients receiving bridging anticoagulation with a therapeutic-dose of LMWH and are undergoing high-bleeding-risk surgery, resumption of the therapeutic dose of LMWH is recommended at 48 to 72 h after surgery instead of within 24 h following surgery. |
| In moderate-to-high-risk patients receiving acetylsalicylic acid who require non-cardiac surgery, treatment with acetylsalicylic acid is recommended to be continued around the time of surgery instead of discontinued at 7 to 10 d prior to surgery. |
| In patients with a coronary stent who require surgery, deferment of surgery is recommended at 6 wk or 6 mo after the placement of a bare-metal or drug-eluting stent, respectively, instead of initiating surgery during these time periods. |
| In patients requiring surgery within 6 wk or 6 mo of the placement of a bare-metal or drug-eluting stent, respectively, continuing perioperative antiplatelet therapy is recommended instead of stopping therapy at 7 to 10 d prior to surgery. |

Modified from Douketis *et al*[65]. LMWHs: Low-molecular-weight heparins.